Emma Reeve

Emma Reeve joined the Editas MediCine Board of Directors in September 2021. Emma is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies.

Most recently, Emma served as Chief Financial Officer of Constellation Pharmaceuticals, Inc, a development-stage oncology company, prior to its acquisition by Morphosys AG In 2021. Emma led Constellation's IPO in 2018.

Prior to Constellation, Emma acted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out.